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The medical community relies on scientific evidence to 
guide clinical practice. Evidence from systematic reviews, 
randomized controlled clinical trials (RCTs), case–control or 
cohort studies, observational studies, and expert opinions are 
used to make disease-specific practice recommendations. 
More than 100 grading systems are used to rate the strength 
of these recommendations (West et al., 2002). A centralized 
and transparent method for evaluating and comparing these 
studies with the goal of translating evidence-based medi-
cine to clinical practice guidelines is the cornerstone of two 
such validation scales: the Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE) and 
Strength of Recommendation Taxonomy (SORT).
In the GRADE system, one frames a question, chooses 
critical and important outcomes by which to judge the exist-
ing body of evidence, rates the quality for each outcome, and 
finally decides on the direction (for or against) and strength 
(strong or weak) for the recommendation considered. The 
SORT method is a simpler rating scale that judges the study 
quality and strength of recommendation based on patient-ori-
ented evidence (Table 1). Whereas GRADE and SORT evaluate 
the body of evidence to establish sound guidelines, the AGREE 
(Appraisal of Guidelines Research and Evaluation) instrument 
provides a framework for assessing the quality of development 
of clinical practice guidelines. AGREE is a generic instrument 
that provides an assessment of the validity and likelihood that 
the stated guideline will achieve its outcome.
GRADING OF RECOMMENDATIONS ASSESSMENT, 
DEVELOPMENT, AND EVALUATION (GRADE)
The GRADE international group is composed of guidelines 
developers, systematic reviewers, clinicians, public health offi-
cers, researchers, methodologists, and other health profession-
als from around the world (Mustafa et al., 2013). The GRADE 
approach has been adopted by more than 65 organizations 
worldwide, including the World Health Organization, the 
US Centers for Disease Control and Prevention, the Cochrane 
Collaboration, and the American College of Chest Physicians, 
and it has become an international standard for guideline 
development (Guyatt et al., 2013).
The GRADE process begins with asking a clinically rel-
evant, well-designed clinical question composed of four 
elements: a patient, problem, or population; an intervention; 
a comparison intervention; and an outcome. The second step 
in the GRADE system is to gather the best evidence to answer 
the question. The third step is assessing the quality of evi-
dence and the confidence in the estimates of the treatment. 
ADVANTAGES AND LIMITATIONS 
GRADE
•  Adopted by more than 65 organizations worldwide 
as an international standard for guideline 
development.
•  Explicitly evaluates relevant outcomes and 
considers risks, benefits, patient expectations, and 
resource utilization in reaching recommendations.
•  Using GRADE is difficult and requires expertise in 
statistics.
SORT
•  Adopted by the American Academy of 
Dermatology.
•  Simple and easily applied by authors and 
physicians. 
•  Advocates the use of patient-oriented rather than 
disease-oriented outcomes.
•  Overly simplified instrument that is not applied 
internationally. 
AGREE
•  Validated instrument that assesses the quality of 
guideline development.
•  Assesses six domains in guideline development: 
scope and purpose, stakeholder involvement, 
rigor of development, clarity and presentation, 
applicability, and editorial independence.
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The fourth step of the process is assessing the values and 
preferences of the target population regarding their beliefs 
and expectations for their health and life. This step refers to 
the process in which individuals weigh the potential benefits, 
harms, costs, limitations, and inconveniences of treatment 
options in relation to one another. With this information, the 
panel is more equipped to accurately define the trade-off 
between the benefits (desirable outcome) and risks (unde-
sirable consequences) for a particular intervention. Ideally, 
“the panel” (guideline developers) will conduct a systematic 
review summarizing relevant studies regarding the patient’s 
values and preferences. The greater the variability or uncer-
tainty in values and preferences, the more likely a weak rec-
ommendation is warranted (Andrews et al., 2013).  
The overall strength of recommendation is based on the 
balance of risks and benefits, the quality of evidence, the 
values and preferences of the patients, and costs required 
for the treatment. Each component is given equal weight 
in relation to the other components. This strength of rec-
ommendation ranges on a continuum of categories from 
“strongly for” to “strongly against” the intervention (Table 
1). If the panel is highly confident of the balance between 
desirable and undesirable consequences, they make a 
strong recommendation for (desirable outweighs undesir-
able) or against (undesirable outweighs desirable) an inter-
vention (Andrews et al., 2013). 
Guideline panels may also choose to make special recom-
mendations when there is insufficient evidence, for example, 
an “only-in-research” recommendation. This recommenda-
tion is used when further research may reduce uncertainty 
The fourth step evaluates the trade-off between risks and 
benefits, reflecting the best assessment of patients’ perspec-
tive of the evidence before making the final recommendation 
(Guyatt et al., 2013) (Figure 1).
The study design determines the initial quality of evidence 
rating. RCTs start as high-quality evidence, whereas observa-
tional studies begin as low-quality evidence. This ranking can 
be upgraded or downgraded based on specific factors that 
can affect the quality of evidence. Factors that can lower the 
quality of evidence include study limitations, inconsistencies 
in the results, indirectness of evidence, imprecision in the 
estimates, and publication bias. The rating can be upgraded 
if the study shows the presence of a dose–response effect or a 
large magnitude of the estimated effect. 
After assessing all the domains, the body of evidence per out-
come is categorized as high (++++), moderate (+++), low (++), 
or very low (+) (Mustafa et al., 2013). The quality of evidence 
rating is summarized in the Evidence Profile (EP) table, which 
includes an explicit judgment of each factor that determines the 
quality of evidence. Table 2 is an example of a transparent and 
concise way of showing the guideline panel judgments about 
the domains. It also contains the Summary of Findings Table 
(SoF). The SoF is a quantitative assessment of the confidence 
in the estimates of effects (i.e., relative risk), without a qualita-
tive judgment of the evidence rating that is provided in the EP 
table. The EP and the SoF tables serve different purposes and are 
directed toward different audiences. EP are intended for review 
authors and anyone who questions a quality of assessment. SoF 
are designated for a broader audience, such as users of system-
atic review and guidelines (Guyatt et al., 2011).
Table 1. Comparison between GRADE and SORT with regard to the strength of recommendation and the quality of evidence
Strength of recommendation Quality of the evidence
GRADE Strong for = benefits outweigh risks  
of the intervention
Strong against = risks outweigh benefits  
of the intervention
Weak = most informed people would choose this 
recommendation but a substantial number would 
not (risks and burdens finely balanced)
High quality = further research is very 
unlikely to change our confidence in the 
estimate of effect
Moderate quality = further research is likely 
to have an important impact on our con-
fidence in the estimate of effect and may 
change the estimate
Low quality = further research is very likely 
to have an important impact on our confi-
dence in the estimate of effect and is likely 
to change the estimate
Very low quality = any estimate is very 
uncertain
SORT A = based on consistent and good quality  
patient-oriented evidence
B = based on inconsistent or limited quality  
patient-oriented evidence
C = based on consensus, usual practice, opinion, 
disease-oriented evidence or case series
Level 1 = good quality, patient-oriented
Level 2 = limited quality, patient-oriented
Level 3 = other evidence (usual practice, 
opinion, disease oriented evidence)
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about the intervention and further research is considered of 
good value for the anticipated costs. Alternatively, the panel 
may decide not to make recommendations for or against a par-
ticular strategy if they find the strength in the estimate is too 
low, the trade-off between risks and benefits is too close, or 
values, preferences, and resource implications are not known 
(Andrews et al., 2013). The main limitation for using GRADE is 
that it is a complex methodology with a steep learning curve. 
STRENGTH OF RECOMMENDATION TAXONOMY (SORT)
SORT was developed by the editors of U.S. Family Medicine 
and Primary Care journals and the Family Practice Inquiries 
Network as an initiative to construct a unified taxonomy that 
allows authors to rate individual studies or bodies of evi-
dence (Ebell et al., 2004). The SORT approach is the main 
methodology that the American Academy of Dermatology 
utilizes in its guideline development process.
The SORT process addresses the quality, quantity, and 
consistency of evidence, and it emphasizes the use of 
patient-oriented outcomes that measure changes in morbid-
ity or mortality (Ebell et al., 2004). The expert panel reviews 
the bodies of evidence for each of the recommendations and 
assigns a strength of recommendation on a scale of A through 
Question/recommendation: Should pulmonary rehabilitation vs. usual community care be used for COPD with recent exacerbation?
Population: Patients with COPD and recent exacerbation of their disease
Intervention: Pulmonary rehabilitation vs. no rehabilitation
Setting (if relevant): Outpatient
tnemgdujgnicneuflnisniamodbuStnemgdujrofnosaeRtnemgduJniamodnoisiceD
Balance of desirable and undesirable
outcomes
Given the best estimate of typical values and
preferences, are you confident that the
benefits outweigh the harms and burden or
vice versa?
The desirable consequences are substantial (including
substantial reduction in hospitalization, small but
important reduction in mortality, and improvement
in quality oflife that exceeds the minimal important
difference) and valued highly. The undesirable
consequences, inconvenience, and burden are
relatively minor and associated with minimal
disutility.
Baseline risk for desirable and undesirable outcomes:
Is the baseline risk similar across subgroups?
Should there be separate recommendations for
subgroups?
Relative risk for benefits and harms:
Are the relative benefits large?
Are the relative harms large?
Requirement for modeling:
Is there a lot of extrapolation and modeling required
for these outcomes?
Typical values:
What are the typical values?
Are there differences in the relative value of the
critical outcomes?
Confidence in estimates of effect (quality of
evidence)
Is there high or moderate quality evidence?
There is moderate-(mortality, function, and quality-of-
life outcomes)-to-high (hospitalizations) quality
evidence for the desirable consequences, and quality
evidence for the undesirable (burden)
Confidence in estimates of benefits and downsides,
confidence in estimates of resource use. Consider all
critical outcomes, including the possibility that some
may not be measured.
Key reasons for rating evidence down or rating up
Values and preferences
Are you confident about the typical values
and preferences and are they similar across
the target population?
We can be confident that patients place a high value
on avoiding hospitalizations and mortality as well as
improving quality oflife and a low value on avoiding
the inconvenience associated with rehabilitation.
We can be confident that these values vary little among
patients with chronic respiratory disease.
Source of typical values (panel or study of general
population or patients)
Source of estimates of variability and extent of variability
Method for determining values satisfactory for this
recommendation
Resource implications
Are the resources worth the expected net
benefit from following the
recommendation?
There are resources required to provide pulmonary
rehabilitation but these are balanced by decreased
resource needs as a result of decreased
hospitalizations and net cost is well worth it given the
desirable outcomes.
What are the costs per resource unit?
Feasibility:
Is this intervention generally available?
Opportunity cost:
Is this intervention and its effects worth
withdrawing or not allocating resources from
other interventions
Differences across settings:
Is there lots of variability in resource requirements
across settings?
Overall strength of recommendation Strong The guideline panel recommends that patients with recent exacerbations of their COPD undergo pulmonary
rehabilitation (Note: this is a hypothetical recommendation developed for this article and not intended for
clinical decision making).
Evidence to recommendation synthesis The moderate-to-high confidence in the moderate-to-large magnitude of effects on highly valued outcomes, and the moderate-to-high
confidence that undesirable outcomes are modest and their avoidance not highly valued suggest a strong recommendation.
COPD, chronic obstructive pulmonary disease.
Reprinted with permission from Andrews et al., 2013.
1. Framing the questions
Using PICO (patient/intervention/comparator/outcome)
4. Trade-off between benefits and risks
(Values and preferences)
5. Recommendation
(Estimate of effect, condence estimate and the patient perspective)
3. Quality of evidence
Assessment of condence in the estimate of treatment effect
2. Treatment effects
Summary of best available evidence, focusing on critical outcomes
Figure. 1. The GRADE process. Adapted with permission from Guyatt et al., 
2013.
Table 2. Evidence to recommendation framework 
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C. For example, consistent and good-quality evidence for 
treatment at an A-level rating would include a systematic 
review/meta-analysis with consistent results or a high-qual-
ity, large individual RCT. 
An A-level recommendation is based on consistent and 
good-quality, patient-oriented evidence. A B-level rec-
ommendation is based on inconsistent or limited-quality 
patient-oriented evidence. A C-level recommendation 
is based on consensus, usual practice, opinion, disease-
oriented evidence, or case series for studies of diagnosis, 
treatment, prevention, or screening (Table 1). The main 
limitation of SORT is that it is an overly simplified instru-
ment that is not applied internationally.
APPRAISAL OF GUIDELINES RESEARCH AND EVALUATION 
(AGREE)
Whereas GRADE and SORT evaluate the body of evi-
dence to establish sound guidelines, the AGREE instru-
ment assesses the quality of the development of clinical 
practice guidelines. The quality of guidelines is based on 
the confidence that potential biases have been addressed 
adequately, that recommendations are both internally 
and externally valid, and that they are feasible for prac-
tice. New or existing guidelines and updates of existing 
guidelines may be appraised with AGREE. It is a validat-
ed tool with a 4-point numerical scoring system, rang-
ing from 1 (representing strongly disagree) to 4 (strongly 
agree). Scores reflecting inadequate quality are assigned 
a score ≤2. This instrument can be applied to any disease 
area, including those in diagnosis, health promotion, and 
treatment.
AGREE is composed of 23 key items encompassed 
within six domains. Each domain is intended to capture 
a different dimension of the guideline quality: scope and 
purpose, stakeholder involvement, rigor of development, 
clarity and presentation, applicability, and editorial inde-
pendence. The domain score is calculated by adding all 
of the individual item scores in a domain and standard-
izing the total as a percentage of the maximum possible 
score for that domain. Each domain score may be use-
ful for comparing guidelines and will aid in the decision 
whether to use that guideline. There is no set threshold for 
the domain score by which to define a “good” or “bad” 
guideline. Finally, an overall assessment is made as to the 
quality of the guideline, taking each of the appraisal cri-
teria into account and rating it as “strongly recommend,” 
“recommend (with provisos or alteration),” “would not 
recommend,” or “unsure” (AGREE Collaboration, 2001). 
Recently, AGREE was modified to AGREE II. The purpose 
of this updated version was to improve reliability, validity, 
and supporting documentation. The newer version contin-
ues to have 23 items and six domains, whereas the rating 
scale for each domain has become more detailed, using a 
7-point rather than 4-point scale. Score 1 is assigned when 
there is no relevant information; scores between 2 and 6 
are given when the domain does not meet the full criteria; 
and a maximum score of 7 is given to exceptional reports 
(AGREE Next Steps Consortium, 2009).
1.  Factors that may decrease the strength of evidence 
for randomized controlled trials (RCTs) in GRADE 
include all of the following except
A. High likelihood of publication bias.
B. Inconsistency.
C. Large or very large treatment effect.
D. Indirectness of evidence.
2.  Which of the following is false regarding AGREE?
A.  It is a method of grading the strength  
of a recommendation.
B.  It can be applied to any disease of interest.
C.  It is an instrument that assesses the quality of the 
development of clinical practice guidelines.
D.  It has no set threshold for the domain score by 
which to define a “good” or “bad” guideline.
3.  Which of the following is false about GRADE?
A.  It has been adopted by more than 65 organiza-
tions worldwide.
B.  It was developed by an international group 
composed of guidelines developers, systematic 
reviewers, clinicians, public health officers, 
researchers, methodologists, and other health 
professionals.
C.  It explicitly evaluates outcomes and sets forth 
recommendations.
D.  It assigns strength of recommendations on a 
scale of A through C.
4.  Regarding the SORT process, all of the following are 
true except
A.  It is a method for assessing patient-oriented  
versus disease-oriented evidence.
B.  It is a complicated methodology that may be a 
barrier for widespread use.
C.  It is simple and easily applied to daily practice 
by authors and physicians.
D.  It assigns a strength of recommendations on a 
scale of A through C and quality of the evidence 
on levels 1 through 3.
5.  The Evidence Profile table
A.  Provides a qualitative judgment of the evidence 
rating.
B.  Is directed toward users of systematic reviews.
C.  Is part of the SORT process.
D.  Summarizes the values and preferences of the 
target population.
QUESTIONS
This article has been approved for 1 hour of Category 1 CME credit.  
To take the quiz, with or without CME credit, follow the link under  
the “CME ACCREDITATION” heading.
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SUMMARY
The AGREE instrument has been applied towards the criti-
cal appraisal of clinical practice guidelines and adaptation 
in evidence-based guidelines for “prevention of skin cancer” 
by the German Guideline Program in Oncology. The rigor-
ous inclusion criteria required by the AGREE instrument nar-
rows the 480 citations related to the topic "prevention of skin 
cancer" to only 12 studies. The strict criteria needed to be 
fulfilled by the AGREE tool demonstrate that methodological 
flaws are an important obstacle in the development of practi-
cal guidelines (Petrarca et al., 2013). The AGREE instrument 
was also chosen as the appraisal tool for evaluation of quality 
of clinical practical guidelines for treatment of psoriasis vul-
garis, 2006-2009 (Tan et al., 2010).
GRADE and SORT are two methods of evaluating a body 
of evidence and the quality of studies to create a comprehen-
sive recommendation. The AGREE instrument is a validated 
quantitative scoring method created to systematically assess 
the quality of practice guidelines. Knowledge of these com-
monly applied grading systems is important for the informed 
dermatologist and clinician to understand for clinical prac-
tice and guideline development.
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A PowerPoint slide presentation appropriate for teaching purposes is available 
at http://dx.doi.org/10.1038/jid.2014.335.
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